Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenetic Biosciences, Inc.XBIO · Entity 8008 | Director | July 19, 2019 | July 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenetic Biosciences, Inc.
Report date July 19, 2019 · Filed July 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 93,603 |
Reported balance
After 2019-07-19 transaction · row 1
1 source rowRow 1 · 2019-07-19 · Grant · Acquired 93,390 · Balance 93,603 F1: Shares acquired in connection the closing of the transaction contemplated by that certain Share Purchase agreement, dated March 1, 2019, with Hesperix SA, a Swiss corporation ("Hesperix"), the owners of Hesperix (each, a "Seller" and collectively, the "Sellers"), and Alexey Andreevich Vinogradov, as the representative of each Seller. The Reporting Person was a Seller in the transaction. On the closing date, the closing price of the Issuer's common stock was $4.85. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired in connection the closing of the transaction contemplated by that certain Share Purchase agreement, dated March 1, 2019, with Hesperix SA, a Swiss corporation ("Hesperix"), the owners of Hesperix (each, a "Seller" and collectively, the "Sellers"), and Alexey Andreevich Vinogradov, as the representative of each Seller. The Reporting Person was a Seller in the transaction. On the closing date, the closing price of the Issuer's common stock was $4.85.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2019 Filed Jul 23, 2019 22:50 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantCommon Stock | 93,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-19-002304 · ownership.xml · nonDerivative · entry 1 Genkin Dmitry · CIK 0001711592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,603 F1 · price: Shares acquired in connection the closing of the transaction contemplated by that certain Share Purchase agreement, dated March 1, 2019, with Hesperix SA, a Swiss corporation ("Hesperix"), the owners of Hesperix (each, a "Seller" and collectively, the "Sellers"), and Alexey Andreevich Vinogradov, as the representative of each Seller. The Reporting Person was a Seller in the transaction. On the closing date, the closing price of the Issuer's common stock was $4.85. Read SEC document |
| March 14, 2018 Filed Jan 31, 2019 21:30 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | OtherCommon Stock | 29,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001662252-19-000014 · ownership.xml · nonDerivative · entry 1 Genkin Dmitry · CIK 0001711592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,549 F1 · kind: On March 14, 2018, the Reporting Person transferred 29,452 shares to a third party as part of a settlement agreement dated October 18, 2017. F1 · price: On March 14, 2018, the Reporting Person transferred 29,452 shares to a third party as part of a settlement agreement dated October 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.